JNJ-95437446

Phase 1Small molecule

Johnson & Johnson

JNJ-95437446 is one of 16 small molecule programs targeting Colorectal Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal NeoplasmsRecruiting

Colorectal NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

16 competitors in Colorectal Neoplasms

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

2 2

Rybrevant

Johnson & Johnson

Phase 3

2 3

Camptosar

Pfizer

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

3 5

Erbitux

IImclone

Phase 3

2 6

Camptosar

EEastern Cooperative Oncology Group

Phase 3

1 7

5-Fluorouracil

Merck & Co.

Phase 3

3 8

Leucovorin Calcium/levoleucovorin

Johnson & Johnson

Phase 3

2 9

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 1

1 10

FOLFIRI

Amgen

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Colorectal Neoplasms

NCT07107230

Clinical

Trials by Indication[1]

Colorectal Neoplasms1 trial

A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07107230·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JNJ-95437446. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-95437446 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-95437446. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Johnson & Johnson

JNJ-95437446

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Colorectal Neoplasms1 trial

References

Drug Info

Quick Facts

Related News